T Berg, M von Wagner, S Nasser, C Sarrazin, … - Gastroenterology, 2006 - Elsevier Background & Aims: The treatment of patients infected with hepatitis C virus
(HCV) type 1 remains a challenge necessitating innovative strategies to improve
treatment outcome. The extension of treatment duration beyond 48 weeks is ... Cited by 246 - Related articles - All 18 versions
- ►sgmjournals.org P Simmonds - Journal of General Virology, 2004 - Soc General Microbiol In the 15 years since the discovery of hepatitis C virus (HCV), much has been
learned about its role as a major causative agent of human liver disease and its
ability to persist in the face of host-cell defences and the immune system. ... Cited by 207 - Related articles - BL Direct - All 6 versions
JL Dienstag, JG McHutchison - Gastroenterology, 2006 - Elsevier In the United States, hepatitis C virus (HCV) infection accounts for
approximately 40% of all chronic liver disease, results in an estimated
8000–10,000 deaths annually, and is the most frequent indication for ... Cited by 161 - Related articles - All 17 versions
VG Bain, KD Kaita, EM Yoshida, MG Swain, … - Journal of hepatology, 2006 - Elsevier Results: A 2 log 10 IU/mL or greater reduction in hepatitis C virus (HCV) RNA at
Week 4 was observed in 69% (18/26) of patients who received the higher alb-IFN
doses of 900 and 1200 μg. The mean HCV RNA reduction at Week 4 in these ... Cited by 54 - Related articles - All 9 versions
V Bocci, 2005 - books.google.com A CIP Catalogue record for this book is available from the Library of Congress.
ISBN 1-4020-3139-4 (HB) ISBN 1-4020-3140-8 (e-book) Published by Springer, PO
Box 17, 3300 AA Dordrecht, The Netherlands. Sold and distributed in North. ... Cited by 47 - Related articles
MS Khuroo, MS Khuroo, ST Dahab - Alimentary Pharmacology and Therapeutics, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 38 - Related articles - BL Direct - All 4 versions
R Moucari, MP Ripault, V Oulès, M Martinot- … - Journal of hepatology, 2007 - Elsevier Forty-four patients (28.6%) achieved sustained virological response (SVR). Rapid
(week 4) and early (week 12) virological response had high negative predictive
values of SVR (94% and 97%, respectively); however positive predictive ... Cited by 34 - Related articles - All 9 versions
M Sherman, EM Yoshida, M Deschenes, M … - British Medical Journal, 2006 - gut.bmj.com Background: The management of patients with chronic hepatitis C who have
relapsed or failed to respond to interferon based therapies is an important
issue facing hepatologists. ... Aims: We evaluated the efficacy and ... Cited by 34 - Related articles - BL Direct - All 4 versions
- ►asnjournals.org KC Abbott, KL Lentine, JR Bucci, LY Agodoa, … - Journal of the American Society of Nephrology, 2004 - Am Soc Nephrol Complications associated with use of donor hepatitis C–positive kidneys
(DHCV+) have been attributed primarily to posttransplantation liver disease (as
a result of hepatitis C disease). The role of posttransplantation diabetes ... Cited by 33 - Related articles - All 4 versions
